In addition, exosomes which targeting NLRP3 and its downstream IL-1β offer an anti-inflammation therapy method without increasing the risk of infection, as anti-IL-1β therapy might directly induce immunosuppression (Ridker et al., 2017). This evidence concerns the gene IL1B and infection.